Edition:
United States

Viking Therapeutics Inc (VKTX.OQ)

VKTX.OQ on NASDAQ Stock Exchange Capital Market

18.20USD
21 Sep 2018
Change (% chg)

$-0.77 (-4.06%)
Prev Close
$18.97
Open
$18.80
Day's High
$20.01
Day's Low
$17.84
Volume
8,146,828
Avg. Vol
938,711
52-wk High
$24.00
52-wk Low
$1.21

Chart for

About

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip... (more)

Overall

Beta: 2.86
Market Cap(Mil.): $1,103.97
Shares Outstanding(Mil.): 60.66
Dividend: --
Yield (%): --

Financials

  VKTX.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -0.56 -- --
ROI: -27.77 1.50 12.72
ROE: -27.77 0.19 14.85

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc's shares more than doubled in value on Tuesday after promising data from a mid-stage trial of its fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals .

Sep 18 2018

UPDATE 1-Viking shares soar as liver disease drug succeeds in mid-stage study

Sept 18 Viking Therapeutics Inc's shares more than doubled on Tuesday after its experimental liver disease treatment met the goals of a mid-stage trial by lowering cholesterol and liver fat levels in patients.

Sep 18 2018

Viking Therapeutics liver drug succeeds in mid-stage study

Sept 18 Viking Therapeutics Inc said on Tuesday its experimental liver disease treatment met the main goals of a mid-stage trial by reducing cholesterol and liver fat in patients.

Sep 18 2018

BRIEF-Viking Therapeutics Q1 Loss Per Share $0.08

* VIKING THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

Earnings vs. Estimates